1 enrolling by invitation, 1 terminated, 1 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Enrolling by invitation 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Enrolling by invitation 1, Withdrawn 1 |
Follow Neutropenia, severe chronic: new trials by email Literature Review of Neutropenia, severe chronic trials Research Report on Neutropenia, severe chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ANF-Rho in the Treatment of Chronic Neutropenia ANF-Rho - Neutropenia, Severe Chronic | Phase 1 / Phase 2 | Withdrawn | Prolong Pharmaceuticals | 2015-10-01 | 2019-03-06 | |
| Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases CD3/CD19 negative allogeneic hematopoietic stem cells - Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 16 | 2013-06-20 | 2025-12-15 |
| Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Ezatiostat Hydrochloride - Severe Chronic Neutropenia | Phase 2 | Terminated | Telik | 9 | 2009-04-01 | 2013-11-25 |
Common Variable Immunodeficiency (1) · Granulomatous Disease, Chronic (1) · Job Syndrome (1) · Neutropenia (1) · Severe Combined Immunodeficiency (1) · Wiskott-Aldrich Syndrome (1)
Cytopenia (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukocyte Disorders (2) · Leukopenia (2) · Agranulocytosis (1) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Chronic Disease (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Repair-Deficiency Disorders (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hemorrhagic Disorders (1)
gamma-Glu-S-BzCys-PhGly diethyl ester (1)
Paul Szabolcs (1) · Prolong Pharmaceuticals (1) · Telik (1)
United States (2)
Gail Brown, MD (1) · Hemant Misra, PhD (1) · Paul Szabolcs, MD (1)